References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2022-3-85-90

mrj-1303

Research Article

КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ

CLINICAL OBSERVATIONS

Рациональное использование рекомендаций по применению уратснижающей терапии: клинические примеры

Rational use of recommendations for urate-lowering therapy: clinical examples

https://orcid.org/0000-0003-1191-5831

Елисеев

М. С.

Eliseev

M. S.

Максим Сергеевич Елисеев

115522, Москва, Каширское шоссе, 34А

Maxim Sergeevich Eliseev

34A, Kashirskoe Shosse, Moscow 115522

elicmax@rambler.ru

https://orcid.org/0000-0002-5394-7869

Желябина

О. В.

Zhelyabina

O. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

2022

20062022

1638590

2022

Елисеев М.С., Желябина О.В.

Eliseev M.S., Zhelyabina O.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/1303

Результаты терапии подагры у многих пациентов остаются неудовлетворительными, несмотря на доступность лекарственных средств и наличие рекомендаций по ее лечению. Помимо недостаточной приверженности пациентов лечению, на эту ситуацию среди других причин влияют врачебные ошибки. В статье рассмотрено несколько клинических случаев, демонстрирующих возможности рационального и аргументированного выбора уратснижающей терапии.

The results of gout therapy in many patients remain unsatisfactory, despite the availability of drugs and recommendations for its treatment. In addition to poor adherence to treatment by patients, medical errors and other reasons influence this situation. The article considers several clinical cases demonstrating the possibilities of a rational choice of urate-lowering therapy.

подаграуратснижающая терапияфебуксостатлечениеаллопуринол

gouturate-lowering therapyfebuxostattreatmentallopurinol

Статья спонсируется компанией «АКРИХИН».

This article has been supported by AKRIKHIN.

References1

Барскова ВГ, Насонова ВА. Современная дефиниция подагры. Клиническая геронтология. 2005;11(4):1-6.

Barskova VG, Nasonova VA. Modern definition of gout. Klinicheskaya gerontologiya. 2005;11(4):1-6. (In Russ.).

Punzi L, Scanu A, Galozzi P, et al. One year in review 2020: gout. Clin Exp Rheumatol. Sep-Oct 2020;38(5):807-21. Epub 2020 Oct 2.

Elfishawi MM, Zleik N, Kvrgic Z, et al. The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Populationbased Study over 20 Years. J Rheumatol. 2018 Apr;45(4):574-9. doi: 10.3899/jrheum.170806. Epub 2017 Dec 15.

Елисеев МС, Новикова АМ. Коморбидность при подагре и гиперурикемии: распространенность, причины, перспективы уратснижающей терапии. Терапевтический архив. 2019;91(5):120-8.

Eliseev MS, Novikova AM. Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate-reducing therapy. Terapevticheskii arkhiv. 2019;91(5):120-8. (In Russ.).

Насонов ЕЛ. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 253-64.

Nasonov EL. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTARMedia; 2017. P. 253-64.

Dalbeth N, Stamp LK, Taylor WJ. What is remission in gout and how should we measure it? Rheumatology (Oxford). 2021 Mar 2;60(3):1007-9. doi: 10.1093/rheumatology/keaa853.

Чикина МН, Елисеев МС, Желябина ОВ. Сравнение эффективности и безопасности различных противовоспалительных препаратов при инициации уратснижающей терапии у пациентов с подагрой (предварительные данные). Современная ревматология. 2021;15(2):50-6.

Chikina MN, Eliseev MS, Zhelyabina OV. Comparison of the efficacy and safety of various anti-inflammatory drugs in urate-lowering therapy initiation in patients with gout (preliminary data). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2021;15(2):50-6. (In Russ.). doi: 10.14412/1996-7012-2021-2-50-56.

FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-60. doi: 10.1002/acr.24180. Epub 2020 May 11.

Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurseled care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018 Oct 20;392(10156):1403-12. doi: 10.1016/S0140-6736(18)32158-5.

Pascart T, Norberciak L, Ea HK, et al. Patients With Early-Onset Gout and Development of Earlier Severe Joint Involvement and Metabolic Comorbid Conditions: Results From a Cross-Sectional Epidemiologic Survey. Arthritis Care Res (Hoboken). 2019 Jul; 71(7):986-92. doi: 10.1002/acr.23706. Epub 2019 Jun 12.

Chen-Xu M, Yokose C, Rai SK, et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019 Jun;71(6):991-9. doi: 10.1002/art.40807. Epub 2019 Apr 15.

Чикина МН, Ильиных ЕВ, Елисеев МС. Приверженность уратснижающей терапии при соблюдении национальных рекомендаций по ведению пациентов с подагрой (предварительные данные). Современная ревматология. 2020;14(4):70-5.

Chikina MN, Il'inykh EV, Eliseev MS. Adherence to urate-lowering therapy while following the national guidelines for the management of patients with gout (preliminary evidence). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(4):70-5. (In Russ.). doi: 10.14412/1996-7012-2020-4-70-75.

Елисеева МЕ, Цурко ВВ, Воробьев ПА. Пожилой пациент с подагрой, лечение у терапевта. Клиническая геронтология. 2015;21(5-6):3-9.

Eliseeva ME, Tsurko VV, Vorob'ev PA. Elderly patient with gout, treatment by a therapist. Klinicheskaya gerontologiya. 2015;21(5-6):3-9. (In Russ.).

Mikuls TR, Saag KG. New insights into gout epidemiology. Curr Opin Rheumatol. 2006 Mar;18(2):199-203. doi: 10.1097/01.bor.0000209435.89720.7c.

Weaver AL, Cheh MA, Kennison RH. How PCP education can impact gout management: the gout essentials. J Clin Rheumatol. 2008 Oct;14(5 Suppl):S42-6. doi: 10.1097/RHU.0b013e3181896b1e.

Keenan RT, Lehman RA, O'Brien WR, et al. Gout management in primary care vs. rheumatology: evidence for suboptimal treatment [abstract]. Arthritis Rheum. 2009;60(10):1110

Kuo CF, Luo SF. Gout: Risk of premature death in gout unchanged for years. Nat Rev Rheumatol. 2017 Apr;13(4):200-1. doi: 10.1038/nrrheum.2017.27. Epub 2017 Mar 2.

Елисеев МС. Комментарии к обновленным рекомендациям Американской коллегии ревматологов по лечению подагры. Образ жизни (часть 2). Современная ревматология. 2021;15(2):83-8.

Eliseev MS. Comments on the updated recommendations of the American College of Rheumatology (ACR) for the treatment of gout. Lifestyle (part 2). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2021;15(2):83-88. (In Russ.). doi: 10.14412/1996-7012-2021-2-83-8.

Елисеев МС. Рекомендации Американской коллегии ревматологов (2020 г.) по ведению больных подагрой: что нового и что спорно. Научно-практическая ревматология. 2021;59(2):129-33.

Eliseev MS. Recommendations of the American College of Rheumatology (2020) on the management of patients with gout: what's new and what's controversial. Nauchno-prakticheskaya revmatologiya. 2021;59(2):129-33. (In Russ.).

Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013 Jun; 72(6):826-30. doi: 10.1136/annrheumdis-2012-201676. Epub 2012 Jun 7.

Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009 Jun;68(6):892-7. doi: 10.1136/ard.2008.091462. Epub 2008 Jul 16.

Nuki G, Doherty M, Richette P. Current management of gout: practical messages from 2016 EULAR guidelines. Pol Arch Intern Med. 2017 Apr 28;127(4):267-77. doi: 10.20452/pamw.4001. Epub 2017 Apr 21.

Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017 Jul 1;56(7):1056-9. doi: 10.1093/rheumatology/kex150.

Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10): 1431-46. doi: 10.1002/acr.21772.

Zhu Y, Pandya B, Choi H. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012 Jul;125(7):679-87.e1. doi: 10.1016/j.amjmed.2011.09.033. Epub 2012 May 23.

Roughley M, Belcher J, Mallen C, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015 Apr 1; 17(1):90. doi: 10.1186/s13075-015-0610-9.

Badve SV, Brown F, Hawley CM, et al. Challenges of conducting a trial of uric-acidlowering therapy in CKD. Nat Rev Nephrol. 2011 May;7(5):295-300. doi: 10.1038/nrneph.2010.186. Epub 2011 Feb 15.

Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013 Jan;61(1):134-46. doi: 10.1053/j.ajkd.2012.07.021. Epub 2012 Oct 9.

Елисеев МС. Хроническая болезнь почек: роль гиперурикемии и возможности уратснижающей терапии. Современная ревматология. 2018;12(1):60-5.

Eliseev MS. Chronic kidney disease: the role of hyperuricemia and the possibility of uratelowering therapy. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(1): 60-5. (In Russ.). doi: 10.14412/1996-7012-2018-1-60-65

Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double- Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis. 2015 Dec;66(6):945-50. doi: 10.1053/j.ajkd.2015.05.017. Epub 2015 Jul 30.

Premachandra KH, Day RO, Roberts DM. Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum. Curr Opin Nephrol Hypertens. 2021 Mar 1;30(2): 245-51. doi: 10.1097/MNH.0000000000000691.

Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447-61. doi: 10.1002/acr.21773.

Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

Чикина МН, Елисеев МС. Спорные вопросы терапии подагры. Фарматека. 2020;27(13):58-64.

Chikina MN, Eliseev MS. Controversial issues of gout therapy. Farmateka. 2020;27(13): 58-64. (In Russ.).

Yokose C, Lu N, Xie H, et al. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. CMAJ. 2019 Sep 30; 191(39):E1070-E1077. doi: 10.1503/cmaj.190339.

Елисеев МС. Лечение подагры при хронической болезни почек. Эффективная фармакотерапия. 2021;(17):36-41.

Eliseev MS. Treatment of gout in chronic kidney disease. Effektivnaya farmakoterapiya. 2021;(17):36-41. (In Russ.).

Hu AM, Brown JN. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review. Clin Rheumatol. 2020 Nov;39(11):3287-94. doi: 10.1007/s10067-020-05079-3. Epub 2020 May 16.

Lee JW, Lee KH. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol. 2019 Mar;51(3): 467-73. doi: 10.1007/s11255-018-2051-2. Epub 2019 Jan 2.

Tsuji T, Ohishi K, Takeda A, et al. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. Clin Exp Nephrol. 2018 Dec;22(6):1300-8. doi: 10.1007/s10157-018-1580-4.

Tsukamoto S, Okami N, Yamada T, et al. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clin Rheumatol. 2022 Mar;41(3):911-9. doi: 10.1007/s10067-021-05956-5. Epub 2021 Oct 12.

Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008 Jan;58(1):25-32. doi: 10.1016/j.jaad.2007.08.036. Epub 2007 Oct 24.

Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013 Nov;169(5):1071-80. doi: 10.1111/bjd.12501.

Puig J, Casas E, Ramos T, et al. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity. J Rheumatol. 1989 Jun;16(6):842-4.

Zinger JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986 Jan;29(1):82-7. doi: 10.1002/art.1780290111.

Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J. 2008 May;49(5):384-7.

Lin CW, Huang WI, Chao PH, et al. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study. Int J Clin Pract. 2019 May;73(5):e13316. doi: 10.1111/ijcp.13316. Epub 2019 Feb 28.

Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi: 10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21.

Chikina M, Elisеev M, Sheliabina O. Application of the EULAR 2016 guidelines for urate-lowering therapy in clinical practice (data of a sixmonth prospective study. Ann Rheum Dis. 2020;79:1761.

Чикина МН, Желябина ОВ, Елисеев МС. Влияние уратснижающей терапии на по- казатели качества жизни у пациентов с подагрой. Современная ревматология. 2021; 15(3):62-8.

Chikina MN, Zhelyabina OV, Eliseev MS. Impact of urate-lowering therapy on quality of life indicators in patients with gout. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2021;15(3):62-8. (In Russ.). doi: 10.14412/1996-7012-2021-3-62-68.

Perez-Ruiz F, Dalbeth N. Combination urate-lowering therapy in the treatment of gout: What is the evidence? Semin Arthritis Rheum. 2019 Feb;48(4):658-68. doi: 10.1016/j.semarthrit.2018.06.004. Epub 2018 Jun 20.

https://e.mail.ru/inbox/0:16529805012136409060:0/#:~:text=%D0%B0%20%D0%B2%20%D1%81%D0%BF%D0%B8%D1%81%D0%BA%D0%B5,desc%26pagenum%3D1

The authors declare that there are no conflicts of interest present.